Ocular Therapeutix (OCUL) Price & Analysis

Compare

1,437 Followers

OCUL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.79 - $12.91

Previous CloseN/A

Volume219.73K

Average Volume (3M)1.98M

Market Cap

$2.14B

Enterprise Value$1.29B

Total Cash (Recent Filing)$391.13M

Total Debt (Recent Filing)$76.94M

Price to Earnings (P/E)―

Beta2.01

Next Earnings

Nov 10, 2025

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding173,995,220

10 Day Avg. Volume1,731,320

30 Day Avg. Volume1,975,802

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.60

Enterprise Value/Revenue22.75

Enterprise Value/Gross Profit25.44

Enterprise Value/Ebitda-6.30

Forecast

1Y Price Target

$17.38

Price Target Upside41.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Market OpportunityDiabetic eye disease represents a significant opportunity for Axpaxli.

Regulatory ProgressFDA alignment under SPA for registrational trial in NPDR provides a clear regulatory path forward.

Trial ProgressThe SOL-1 trial is on track to report topline data, indicating strong progress in the ongoing Phase 3 trial.

Bears Say

Competitive PositioningStock is down 4%-7% on the surprise news of the rescue criteria change and confirmation of timelines that put Axpaxli behind Eyepoint's Duravyu in terms of NDA filing.

Investor ConcernsThe change in rescue criteria for the SOL-R trial reflects a more stringent measure, causing concern among investors.

Trial ChangesOcular is changing the rescue criteria in SOL-R to align more closely with real-world practice, which management believes will help facilitate easy adoption in the commercial setting, if approved.

Ocular Therapeutix News

Ocular Therapeutix receives FDA agreement under SPA for trial of AXPAXLI

Ocular Therapeutix (OCUL) announced it has received written agreement regarding a registrational trial design from the U.S. Food...

17d ago

OCUL

Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank

Scotiabank lowered the firm’s price target on Ocular Therapeutix (OCUL) to $20 from $22 and keeps an Outperform...

22d ago

OCUL

Ocular Therapeutix reports Q2 EPS (39c), consensus (35c)

Reports Q2 revenue $13.5M, consensus $13.12M. “We are entering the most important phase of Ocular Therapeutix’s (OCUL) history,...

24d ago

OCUL

Ocular Therapeutix sees cash runway into 2028

Total cash and cash equivalents were $391.1 million as of June 30, 2025. Based on current plans and...

24d ago

OCUL

Promising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix and keeping the price target...

16d ago

OCUL

Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating...

16d ago

OCUL

Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating...

21d ago

OCUL

Ocular Therapeutix Reports Q2 2025 Financial Results

Ocular Therapeutix Inc ( ($OCUL) ) has released its Q2 earnings. Here is a breakdown of the information...

23d ago

OCUL

Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress

Ocular Therapeutix Inc (($OCUL)) has held its Q2 earnings call. Read on for the main highlights of the...

23d ago

OCUL

OCUL Upcoming Earnings Report: What to Expect?

Ocular Therapeutix Inc (OCUL) is scheduled to report 2nd quarter earnings on 08/05/2025, before the market opens. Regarding...

26d ago

OCUL

Ocular Therapeutix Approves Key Amendments at Annual Meeting

The latest announcement is out from Ocular Therapeutix ( ($OCUL) ). On June 11, 2025, Ocular Therapeutix held...

3M ago

OCUL

Ocular Therapeutix’s Promising Clinical Trials and Strategic Advancements Justify Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (OCUL...

3M ago

OCUL

Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential

Analyst Serge Belanger of Needham maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the...

3M ago

OCUL

Ocular Therapeutix’s Promising Developments and Strategic Execution Justify Buy Rating

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating...

3M ago

OCUL

OCUL FAQ

What was Ocular Therapeutix’s price range in the past 12 months?

Ocular Therapeutix lowest stock price was $5.79 and its highest was $12.91 in the past 12 months.

What is Ocular Therapeutix’s market cap?

Ocular Therapeutix’s market cap is $2.14B.

When is Ocular Therapeutix’s upcoming earnings report date?

Ocular Therapeutix’s upcoming earnings report date is Nov 10, 2025 which is in 73 days.

How were Ocular Therapeutix’s earnings last quarter?

Ocular Therapeutix released its earnings results on Aug 05, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.357 by -$0.033.

Is Ocular Therapeutix overvalued?

According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ocular Therapeutix pay dividends?

Ocular Therapeutix does not currently pay dividends.

What is Ocular Therapeutix’s EPS estimate?

Ocular Therapeutix’s EPS estimate is -0.38.

How many shares outstanding does Ocular Therapeutix have?

Ocular Therapeutix has 173,995,220 shares outstanding.

What happened to Ocular Therapeutix’s price movement after its last earnings report?

Ocular Therapeutix reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.357. Following the earnings report the stock price went down -2.834%.

Which hedge fund is a major shareholder of Ocular Therapeutix?

Currently, no hedge funds are holding shares in OCUL

Ocular Therapeutix Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.41%

Trailing 12-Months

Asset Growth

-12.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. The company specializes in creating sustained-release drug products using its proprietary hydrogel platform technology, which allows for extended delivery of medications to the ocular surface. Ocular Therapeutix's core products include Dextenza, a drug-eluting implant for the treatment of post-surgical pain and inflammation, and OTX-TP, an investigational product for the treatment of glaucoma and ocular hypertension.

Ocular Therapeutix (OCUL) Earnings & Revenues

Historic Earnings Reports

OCUL Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlighted significant advancements in clinical trials and a strong financial position, indicating optimism about the future potential of AXPAXLI. The challenges mentioned, such as adjustments in rescue criteria, were addressed strategically, reflecting confidence in the drug's profile.View all OCUL earnings summaries

OCUL Stock 12 Month Forecast

Average Price Target

$17.38

▲(41.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","9.25":"$9.25","13.5":"$13.5","17.75":"$17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.25,13.5,17.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.618461538461538,13.316923076923077,14.015384615384615,14.713846153846154,15.412307692307692,16.11076923076923,16.80923076923077,17.50769230769231,18.206153846153846,18.904615384615383,19.603076923076923,20.301538461538463,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.34,12.76,13.18,13.6,14.02,14.44,14.86,15.28,15.7,16.119999999999997,16.54,16.96,{"y":17.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.92,12.08,12.24,12.4,12.56,12.72,12.879999999999999,13.04,13.2,13.36,13.52,13.68,13.84,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >